Complement Pathway Inhibition Therapy for Neurodegeneration

Complement Pathway Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
• Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
• Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
• Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HT

Complement Pathway Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
• Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
• Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
• Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HTT](/genes/htt)
• Mechanisms: [[neuroinflammation](/mechanisms/neuroinflammation)](/mechanisms/[neuroinflammation](/mechanisms/neuroinflammation)), [[mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)](/mechanisms/mitochondrial-dysfunction), [[lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)](/mechanisms/lysosomal-dysfunction), [[protein aggregation](/mechanisms/protein-aggregation)](/mechanisms/protein-aggregation), [[oxidative stress](/mechanisms/oxidative-stress)](/mechanisms/oxidative-stress), [[autophagy](/mechanisms/autophagy)](/mechanisms/[autophagy](/mechanisms/autophagy)), [[synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction](/mechanisms/[synaptic dysfunction](/mechanisms/synaptic-dysfunction)-dysfunction)
• Therapeutics: [[gene therapy](/therapeutics/gene-therapy-neurodegeneration)](/therapeutics/gene-therapy-neurodegeneration), [ASOs](/therapeutics/antisense-oligonucleotides), [CRISPR gene editing](/therapeutics/crispr-gene-editing-neurodegeneration), [deep brain stimulation](/therapeutics/deep-brain-stimulation)
• Pathways: [complement system](/mechanisms/complement-system-pathway), [neurotrophic signaling](/mechanisms/neurotrophic-factor-signaling), [cell death pathways](/mechanisms/cell-death-pathways-neurodegeneration)

Overview

Complement Pathway Inhibition Therapy targets the classical complement cascade — specifically C1q, C3, and the membrane attack complex (MAC/C5b-C9) — to prevent pathological [synaptic dysfunction](/mechanisms/synaptic-dysfunction) pruning, [neuroinflammation](/mechanisms/neuroinflammation), and myelin damage across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, and aging. The complement system normally functions in [synaptic dysfunction](/mechanisms/synaptic-dysfunction) refinement during development, but in neurodegenerative disease, this pathway is pathologically reactivated, driving excessive synapse elimination that correlates directly with cognitive decline["@stevens2007"][@hong2016].

This therapeutic approach is the first to simultaneously address three complement-mediated damage pathways: C1q-mediated [synaptic dysfunction](/mechanisms/synaptic-dysfunction) tagging, C3a/C3b-mediated [microglia](/cell-types/microglia)l phagocytosis via CR3 receptor, and C5b-C9 MAC-mediated direct neuronal lysis.

Mechanistic Rationale

The Complement Cascade in Neurodegeneration

The complement system comprises over 50 proteins organized into three activation pathways (classical, lectin, alternative). In neurodegeneration, the classical pathway — initiated by C1q binding to vulnerable synapses — is the primary driver of pathological synapse loss[@sullivan2017][@cui2020].

Pathological cascade:

Disease-Specific Evidence

Alzheimer's Disease:

• C1q is elevated in AD hippocampus and colocalizes with amyloid plaques[@hong2016]
• C4B expression is enhanced in AD brains, and C4B haplotypes are linked to AD risk (via the same MHC region as schizophrenia)[@dejanovic2022][@sekar2016]
• C3 deletion prevents age-related cognitive decline in mouse models[@shi2021]
• C3a receptor antagonism improves memory in 5xFAD mice[@yang2023]
• Anti-C1q antibodies prevent synapse loss in APP/PS1 mice[@cui2020]

• C1q infiltration documented in [substantia nigra](/brain-regions/substantia-nigra) pars compacta of PD brains[@bae2018]
• C1q-C3 pathway mediates [alpha-synuclein](/proteins/alpha-synuclein)-induced neurotoxicity in mouse models
• Complement activation correlates with dopaminergic neuron loss

• C1q deficiency or blockade reduces [microglia](/cell-types/microglia)l activation and delays disease onset in SOD1G93A mice[@danek2020]
• C5a receptor blockade reduces [neuroinflammation](/mechanisms/neuroinflammation) and behavioral deficits in ALS models[@wang2022]
• C1q is upregulated in spinal cord of ALS patients and correlates with motor neuron loss

• Complement activation contributes to striatal synapse loss[@presnyakov2017]
• C1q and C3 are elevated in HD post-mortem brain tissue

Therapeutic Strategy

Primary Targets

| Target | Role | Therapeutic Approach |
|--------|------|----------------------|
| C1q | Initiator of classical pathway; tags synapses | Anti-C1q monoclonal antibodies (e.g., ANX007), C1q receptor antagonists |
| C3 | Central node of all complement pathways | C3 convertase inhibitors, C3a receptor antagonists (e.g., CCX168) |
| C5 | Terminal pathway; generates C5a and MAC | Eculizumab/Ravulizumab (approved for PNH/aHUS), anti-C5a antibodies |
| CR3 (ITGAM) | Microglial receptor for C3b; mediates synapse phagocytosis | CR3 antagonists, blocking antibodies |

Multi-Level Inhibition Strategy

Rather than targeting a single complement component, the therapeutic strategy deploys a layered inhibition approach:

Layer 1 — C1q blockade (upstream):

• Prevents [synaptic dysfunction](/mechanisms/synaptic-dysfunction) tagging, the earliest pathological step
• ANX007 (Annexon Pharmaceuticals) is an anti-C1q antibody currently in Phase 2 for ALS (NCT04539015)
• Rationale: Blocking C1q is more physiological than global complement inhibition — it preserves the protective functions of downstream complement while preventing pathological [synaptic dysfunction](/mechanisms/synaptic-dysfunction) tagging

• Neutralizes the pro-inflammatory anaphylatoxin driving [microglia](/cell-types/microglia)l activation
• CCX168 (Chemocentryx/Aurinia) and similar compounds block C3a receptor signaling
• Rationale: C3a antagonism addresses both [neuroinflammation](/mechanisms/neuroinflammation) and [synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction without blocking the protective opsonization cascade entirely

• Prevents MAC formation (direct neuronal lysis) and C5a generation
• Eculizumab/Ravulizumab are FDA-approved biologics with established safety profiles
• Rationale: C5 inhibition preserves C1q-C4 protective functions while blocking terminal pathway damage; approved for paroxysmal nocturnal hemoglobinuria (PNH), demonstrating long-term safety

Biomarker Monitoring

| Biomarker | Source | Utility |
|-----------|--------|---------|
| C1q levels | CSF | Direct read-out of upstream pathway activation |
| C3a | CSF (lumbar puncture) | Downstream pathway activity, dose-response for C3aRA |
| sC5b-9 (soluble MAC) | Serum/CSF | Terminal pathway activation |
| NfL (neurofilament light) | Serum/CSF | Neuronal injury response (confirms [neuroprotection](/therapeutics/neuroprotection)) |
| Synaptic proteins (synaptophysin, PSD95) | CSF | Direct measure of [synaptic dysfunction](/mechanisms/synaptic-dysfunction) preservation |

Disease Coverage

| Disease | Complement Role | Target Priority |
|---------|-----------------|----------------|
| Alzheimer's Disease | C1q tags Aβ-vulnerable synapses; C3 CR3 pathway drives synapse loss; C4 linked to genetic risk | C1q > C3aR > C5 |
| Parkinson's Disease | C1q in [substantia nigra](/brain-regions/substantia-nigra); dopaminergic neuron vulnerability to MAC | C1q > C5 > C3aR |
| ALS | C1q drives [microglia](/cell-types/microglia)l phagocytosis of motor neuron synapses; C5a neurotoxicity | C1q > C3aR > C5 |
| Frontotemporal Dementia | TDP-43 pathology triggers complement; [synaptic dysfunction](/mechanisms/synaptic-dysfunction) vulnerability | C1q > C3aR |
| Huntington's Disease | Striatal synapse loss via complement | C3aR > C1q |
| Aging/Cognitive decline | Low-level chronic complement activation; "inflammaging" | C1q > C5 |

10-Dimension Rubric Score

| Dimension | Score (1-10) | Rationale |
|-----------|-------------|-----------|
| Novelty | 8 | Multi-level complement targeting is novel; upstream C1q inhibition especially cutting-edge |
| Mechanistic Rationale | 9 | Strong genetic (C4, CR3), post-mortem (C1q in AD/PD/ALS brain), and preclinical evidence (C1q KO prevents synapse loss) |
| Root-Cause Coverage | 7 | Addresses [synaptic dysfunction](/mechanisms/synaptic-dysfunction) loss directly, a proximal cause of cognitive/behavioral decline |
| Delivery Feasibility | 6 | Large biologics (antibodies) face BBB challenge; Annexon uses intravitreal/subcutaneous; systemic CNS delivery remains a limitation |
| Safety Plausibility | 7 | Eculizumab has excellent safety profile; C1q blockade preserves protective complement; risk is immunosuppression and infection |
| Combinability | 9 | Highly synergistic with anti-amyloid (reduces complement activation trigger), anti-tau, [TREM2](/genes/trem2) modulators, and synapse-protective approaches |
| Biomarker Availability | 8 | Multiple validated biomarkers (C1q, C3a, sC5b-9, NfL, [synaptic dysfunction](/mechanisms/synaptic-dysfunction) proteins) enable patient selection and dose-response monitoring |
| De-risking Path | 8 | Annexon ANX007 already in Phase 2 for ALS; eculizumab is approved and well-characterized; clear regulatory path (orphan drug designation possible) |
| Multi-disease Potential | 9 | One mechanism addresses synapse loss across AD, PD, ALS, HD, and aging |
| Patient Impact | 8 | Synapse preservation directly addresses the cognitive/functional decline that devastates patients and caregivers |
| Total | 79 | |

Implementation Roadmap

Phase 1: Preclinical (12-18 months)

• Validate C1q/C3aR/C5 combination in mouse models (5xFAD, [alpha-synuclein](/proteins/alpha-synuclein) transgenic, SOD1)
• Identify most effective target (C1q vs. C3aR vs. C5)
• Establish pharmacodynamic biomarkers for Phase 1 dose selection

Phase 2: Phase 1/2a (18-24 months)

• Safety and tolerability of lead compound in healthy volunteers and early AD/PD patients
• Biomarker enrichment: select patients with elevated CSF C1q or C3a
• Synaptic biomarker readouts (CSF synaptophysin, PSD95)

Phase 3: Registration-enabling (24-36 months)

• C1q-enriched AD cohort, primary endpoint: [synaptic dysfunction](/mechanisms/synaptic-dysfunction) preservation (PET ligand or CSF biomarker)
• Parallel ALS cohort (Annexon's existing ANX007 trial provides foundation)
• Adaptive design for dose selection based on Phase 2 biomarker data

Key Academic Centers

• UCSF Memory and Aging Center (David Holtzman — complement in AD)
• Columbia University (Sagd; C1q biology in neurodegeneration)
• Johns Hopkins (Cw; ALS complement mechanisms)
• University of California, Irvine (Frank LaFerla — 5xFAD models)

Potential Partners

• Annexon Pharmaceuticals — ANX007 (anti-C1q) in Phase 2 for ALS, planning AD expansion
• UCB Pharma — Anti-C3 program in development
• Roche/Chugai — Anti-C5 antibodies with BBB-penetrant variants in pipeline

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|------------|
| BBB penetration of antibodies | Medium | High | Explore BBB-shuttle strategies (TfR, LDLR); develop smaller C1q-inhibitory fragments |
| Infection risk from complement inhibition | Medium | High | Careful patient selection (exclude active infections); prophylactic antibiotics where appropriate |
| Insufficient efficacy (single target) | Medium | Medium | Deploy multi-level strategy; use biomarker-guided patient enrichment |
| Precedent risk: C3 KO in HD models paradoxically worsened outcome | Low | Medium | Target downstream receptors (CR3) or terminal pathway (C5) rather than global C3; careful dose titration |

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Grant Opportunities